Saifullah Nasir, MD
Internal Medicine · Schaumburg, ILNPI 1427343938
Payments from drug & device makers
Across 520 payments — averaging $2851.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$770K
- AbbVie$578K
- Boehringer Ingelheim International GmbH$45K
- Amgen$31K
- Boehringer Ingelheim Pharma GmbH & Co.kg$22K
- Ionis Pharmaceuticals, Inc.$19K
- plus $17K from 32 others
Across 2 payments — averaging $108,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$217K
What the payments were for
- Speaking & faculty fees$170%
- Food & beverage$7,039100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,482,526 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $437,403 |
| XareltoRivaroxaban | 104 | $152,447 |
| JardianceEmpagliflozin | 87 | $135,143 |
| EntrestoSacubitril/Valsartan | 63 | $91,905 |
| OzempicSemaglutide | 33 | $55,892 |
| FarxigaDapagliflozin Propanediol | 38 | $51,387 |
| JanuviaSitagliptin Phosphate | 13 | $19,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,566 |
| Metoprolol Succinate | 517 | $8,685 |
| Atorvastatin Calcium | 829 | $8,435 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,311 |
| Potassium Chloride | 216 | $4,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $4,393 |
| Lisinopril | 398 | $3,640 |
| Levothyroxine Sodium | 195 | $3,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $958 | $437,403311 claims |
| Johnson & JohnsonXarelto | $337 | $152,447104 claims |
| Boehringer IngelheimJardiance | $1,239 | $135,14387 claims |
| NovartisEntresto | $12,325 | $91,90563 claims |
| Novo NordiskOzempic | $145 | $55,89233 claims |
| AstraZenecaFarxiga | $461 | $51,38738 claims |
| MerckJanuvia | $69 | $19,58413 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $16,87728 claims |
| AbbVieSynthroid | $578,467 | $1,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Schaumburg
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.